ARK Investment Management 13F: Cuts Veracyte (VCYT) Stake by $49M

ARK Investment Management has cut its stake in Veracyte, Inc. (NasdaqGM: VCYT) by 21%. The firm sold 833,729 shares, bringing its total holdings to 3,053,818 shares. As of the filing, these shares are valued at approximately $144.5 million. This data comes from the latest Form 13F filing with the SEC, reflecting holdings as of the reporting period.

What Changed in ARK Investment Management's Veracyte Position

ARK Investment Management reduced its position in Veracyte, selling 833,729 shares. This reduction brought its total holdings down to 3,053,818 shares, a 21% decrease from the previous 3,887,547 shares. The value of the remaining shares is about $144.5 million.

Other Institutional Activity in Veracyte

Several other funds made notable moves in Veracyte during the same period. BlackRock, Inc. increased its holdings by 43,817 shares, ending with 13,172,618 shares valued at roughly $424.3 million. FMR LLC significantly boosted its stake, adding 2,025,640 shares for a total of 7,763,849 shares worth about $250.1 million. Artisan Partners Limited Partnership, however, trimmed its position by 766,671 shares, leaving it with 5,496,370 shares valued at $177 million. State Street Corp added 682,677 shares, raising its total to 5,043,590 shares, valued at $162.5 million.

Veracyte, Inc. Stock Up 47.6%

Shares of Veracyte, Inc. (NasdaqGM: VCYT) recently traded at $47.33. The company has a market capitalization of around $3.78 billion and a P/E ratio of 43.8. Its forward P/E is 24.9, reflecting growth expectations. Veracyte's beta is 1.984, indicating higher volatility compared to the market. The stock's 52-week range has been between $22.61 and $50.71. It has a 50-day moving average of $39.21 and a 200-day moving average of $38.00. The company's strong liquidity is shown by a current ratio of 9.3 and a quick ratio of 8.7.

Recent Earnings

In its most recent earnings report, Veracyte posted revenue of $541.7 million, showing a growth rate of 21.5%. The company reported an EPS of $1.08, with a net margin of 16.25% and a return on equity of 6.93%. The next earnings announcement is expected on August 5, 2026.

Insider Buying and Selling at Veracyte, Inc.

Several insiders engaged in transactions on June 4, 2026. CEO Marc Stapley sold 138,051 shares at an average price of $50.12 under a planned sale. He also purchased the same number of shares at $36.60 in an unplanned transaction. EVP and General Counsel Annie McGuire sold 3,176 shares at $49.76, and CFO Rebecca Chambers sold 3,561 shares at $49.73, both under planned sales.

Analysts Set New Price Targets

On June 1, 2026, Needham maintained its 'buy' rating on Veracyte with a price target of $57. UBS also maintained a 'buy' rating with a target of $52 on May 6, 2026. Canaccord Genuity has a 'hold' rating with a target of $42. Overall, analysts have a consensus 'buy' rating with a mean price target of $49.10 across 10 opinions.

About Veracyte

Veracyte, Inc. is a diagnostics company based in South San Francisco, California. It provides genomic tests for cancer diagnosis, including thyroid, prostate, bladder, breast, and lung cancers. The company also offers the nCounter analysis system. Founded in 2006, Veracyte is led by CEO Marc Stapley and employs around 755 people.

Bottom Line

ARK Investment Management's reduction in Veracyte shares is a notable move, reflecting its strategic adjustments. Investors often track such filings to gauge institutional sentiment, though these reports are backward-looking. Veracyte remains a significant player in the diagnostics industry, with a solid market position and ongoing analyst interest.